These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28167482)

  • 1. Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients.
    Hussain M; Atif MA; Ghafoor MB
    Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2385-2389. PubMed ID: 28167482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.
    El-Naggar AR; Zaafar D; Elyamany M; Hassanin S; Bassyouni A; Abdel-Latif H
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):254-261. PubMed ID: 30630371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME; Puppala VK; Suboc TM; Malik M; Branum A; Signorelli K; Wang J; Ying R; Tanner MJ; Tyagi S
    Vasc Med; 2017 Jun; 22(3):189-196. PubMed ID: 28145158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect Of Sitagliptin On Glycemic Control, Body Weight, Blood Pressure And Serum Lipid Profile In Type 2 Diabetic Hyperlipidemic Patients.
    Hussain M; Atif MA; Tunio AG; Ali B; Akhtar L; Serwar G
    J Ayub Med Coll Abbottabad; 2016; 28(2):369-372. PubMed ID: 28718546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
    Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
    Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
    Ferjan S; Janez A; Jensterle M
    Metab Syndr Relat Disord; 2017 Dec; 15(10):515-520. PubMed ID: 29064743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
    Hussain M; Shad MN; Akhtar L
    J Pak Med Assoc; 2017 Dec; 67(12):1884-1888. PubMed ID: 29256535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial.
    Osei E; Fonville S; Zandbergen AA; Brouwers PJ; Mulder LJ; Lingsma HF; Dippel DW; Koudstaal PJ; den Hertog HM
    Trials; 2015 Aug; 16():332. PubMed ID: 26242578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
    Göke R; Eschenbach P; Dütting ED
    Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia: Results of a Meta-Analysis.
    Weisser B; Predel HG; Gillessen A; Hacke C; Vor dem Esche J; Rippin G; Noetel A; Randerath O
    High Blood Press Cardiovasc Prev; 2020 Apr; 27(2):157-164. PubMed ID: 32219670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bezafibrate on office, home and ambulatory blood pressure in hypertensive patients with dyslipidemia.
    Ohta Y; Kawano Y; Iwashima Y; Hayashi S; Yoshihara F; Nakamura S
    J Hum Hypertens; 2013 Jul; 27(7):417-20. PubMed ID: 23254592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials.
    Fan M; Li Y; Zhang S
    Medicine (Baltimore); 2016 Jan; 95(2):e2386. PubMed ID: 26765417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment in a preventive cardiology clinic utilizing advanced practice providers effectively closes atherosclerotic cardiovascular disease risk-management gaps among a primary-prevention population compared with a propensity-matched primary-care cohort: A team-based care model and its impact on lipid and blood pressure management.
    Fentanes E; Vande Hei AG; Holuby RS; Suarez N; Slim Y; Slim JN; Slim AM; Thomas D
    Clin Cardiol; 2018 Jun; 41(6):817-824. PubMed ID: 29667200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
    Fukui K; Kawahito H; Wakana N; Kikai M; Terada K; Yamamoto K; Irie D; Kato T; Miyagawa S; Yamada H
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1001-9. PubMed ID: 26195265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
    Mistry GC; Maes AL; Lasseter KC; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
    J Clin Pharmacol; 2008 May; 48(5):592-8. PubMed ID: 18353996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.